

COVID-19 risk alleles – susceptibility or severity?

Matti Pirinen 20.1.2022





Motivation (1/2)

- Consider two GWAS on host phenotypes related to corona virus infection
- Infection GWAS compares infected vs. population controls
 - Lab confirmed SARS-Cov-2 infection OR
 - Physician reported SARS-Cov-2 infection OR
 - Self reported SARS-Cov-2 infection
- Hospitalization GWAS compares hospitalized for COVID-19 vs. population controls
 - Lab confirmed SARS-Cov-2 infection AND
 - Hospitalized for COVID-19



Motivation (2/2)

- Infection GWAS compares infected vs. population controls
- Hospitalization GWAS compares hospitalized for COVID-19 vs. population controls

ABO locus (rs505922-C) DPP9 locus (rs2109069-A)

	OR	P-value	OR	P-value
Infection	1.10 (1.09-1.11)	4e-83	1.04 (1.03-1.05)	2e-13
Hospitalization	1.11 (1.09-1.13)	9e-23	1.12 (1.09-1.14)	2e-21

Is a variant associated with susceptibility to infection or severity of disease?



In this talk

ABO locus (rs505922-T)

DPP9 locus (rs2109069-A)

	OR	P-value	OR	P-value
Infection	0.91 (0.90-0.92)	4e-83	1.04 (1.03-1.05)	2e-13
Hospitalization	0.90 (0.88-0.92)	9e-23	1.12 (1.09-1.14)	2e-21


- > Why do we conclude that ABO is a susceptibility locus and DPP9 is a severity locus?
- How we can quantitatively evaluate to which group a locus belongs from GWAS data?



- Generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes
- Initiated by Andrea Ganna, Mark Daly and Ben Neale in March 2020
- https://www.covid19hg.org/
- Release 6 (June 2021)
 - 64 studies from 24 countries with over 3,300 researchers
 - Hospitalization GWAS of 23,988 hospitalized for COVID-19 vs. population controls (2,834,885)
 - Infection GWAS of 114,516 SARS-Cov-2 infected vs. population controls (2,138,237)
 - Manuscript in medRxiv




Release 6 results (medRxiv)




Cases and controls

Case groups are nested, controls are shared between the two GWAS



Susceptibility variant




Higher frequency in infected than in non-infected but same in hospitalized cases as in all infected

$$\beta_{INF} = \beta_{HOS} > 0$$



Severity variant (1/2)



Higher frequency among hospitalized than among other infected.

Same frequency among infected as among non-infected.


(Since hospitalized is a small part of all infected, non-hospitalized infected have approx. same frequency than non-infected.)



$$\beta_{HOS} > \beta_{INF}$$



Severity variant (2/2)



If cases of infection GWAS were a random set of all infected, then, for a severity variant

$$\beta_{INF}=0.$$

However, cases of infection GWAS is strongly enriched for hospitalized cases and therefore


$$\beta_{INF} > 0$$
.

The weight of hospitalization GWAS in infection GWAS is 0.20.

$$\beta_{INF} \approx 0.2 \, \beta_{HOS} > 0$$



Expected GWAS effects




$$\beta_{INF} = \beta_{HOS} > 0$$

$$\beta_{INF} \approx 0.2 \, \beta_{HOS} > 0$$



Observed GWAS effects



Susceptibility variants


$$\beta_{INF} = \beta_{HOS} > 0$$

Severity variants

$$\beta_{INF} \approx 0.2 \, \beta_{HOS} > 0$$



Models for GWAS effects



Susceptibility variants

$$\beta_{INF} = \beta_{HOS} > 0$$


Severity variants

$$\beta_{INF} \approx 0.2 \, \beta_{HOS} > 0$$

We allow some deviation from theoretical relationships because of biases and approximations.



Which model is more probable?




Bayes formula (with equal prior probabilities of models):

$$\frac{\Pr(\text{Sever.} \mid \widehat{\beta})}{\Pr(\text{Suscep.} \mid \widehat{\beta})} = \frac{\Pr(\widehat{\beta} \mid \text{Sever.})}{\Pr(\widehat{\beta} \mid \text{Suscep.})}$$

	Sever.	Suscep.
ABO	1e-38	1
DPP9	0.99999994	6e-8



Which model is more probable?




7 susceptibility loci 16 severity loci (probability > 99%)

Code and documentation in github / mjpirinen




Release 6 results (medRxiv)






"Line Models" R function soon





Acknowledgements



The COVID-19
Host Genetics Initiative

Mark Daly
Andrea Ganna
Ben Neale
Mattia Cordioli
Gita Pathak
Juha Karjalainen

